利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

50 条记录 (耗时 0.088 秒)

    Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710
    4.
    发明申请
    Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 审中-公开
    用于治疗癌症的方法和组合物，使用2192,2133,6568,8895,9138,9217,9609,9857,9882,10025,20657,21163,25848,25968,32603,32670,33794,5446和94710

    公开(公告)号：US20070087375A1

    公开(公告)日：2007-04-19

    申请号：US11633986

    申请日：2006-12-05

    申请人： John Hunter ,  Mark Williamson ,  Kyle MacBeth ,  Laura Rudolph-Owen ,  Fong-Ying Tsai

    发明人： John Hunter ,  Mark Williamson ,  Kyle MacBeth ,  Laura Rudolph-Owen ,  Fong-Ying Tsai

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： G01N33/5011 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/04 ,  G01N2500/10

    摘要： The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a cancer or cancer. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cancer.

    摘要翻译： 本发明涉及癌症或癌症的诊断和治疗方法。 具体而言，本发明鉴定组织中的2192,2133,6568,8895,9138,9217,9609,9857,9882,10025,20657,21163,25848,25968,32603,32670,3797,45476和94710基因的差异表达 涉及癌症，相对于它们在正常或非癌症疾病状态中的表达，和/或响应于与癌症相关的操作。 本发明描述了各种癌症的诊断评估和预后的方法，以及用于鉴定表现出这种病症倾向的受试者。 本发明还提供了鉴定能够调节癌症或癌症的化合物的方法。 本发明还提供了鉴定和治疗化合物作为癌症治疗的方法。

    Novel nucleic acid sequences encoding G-protein coupled receptors
    8.
    发明申请
    Novel nucleic acid sequences encoding G-protein coupled receptors 审中-公开
    编码G蛋白偶联受体的新型核酸序列

    公开(公告)号：US20060275866A1

    公开(公告)日：2006-12-07

    申请号：US11268745

    申请日：2005-11-07

    申请人： Katherine Galvin ,  Maria Glucksmann ,  Martin Hodge ,  John Hunter ,  Laura Rudolph-Owen ,  Inmaculada Silos-Santiago ,  Nadine Weich

    发明人： Katherine Galvin ,  Maria Glucksmann ,  Martin Hodge ,  John Hunter ,  Laura Rudolph-Owen ,  Inmaculada Silos-Santiago ,  Nadine Weich

    IPC分类号： C07K14/705 ,  C07H21/04 ,  C12P21/06

    CPC分类号： C07K14/705

    摘要： The invention provides isolated nucleic acids molecules, designated 2871, 14926, 44576, 23992, 1983, 52881, 2398, and 52872 nucleic acid molecules, which encode novel G protein-coupled receptor family members that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 proteins, fusion proteins, antigenic peptides and anti-2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供分离的核酸分子，命名为2871,14926,4457,239992,1983,52881,2988和52872核酸分子，其编码编码新多肽的新型G蛋白偶联受体家族成员。 本发明还提供反义核酸分子，含有2871,14926,4576,23992,1983,52881,2398或52872核酸分子的重组表达载体，已经引入了表达载体的宿主细胞，以及非人转基因动物，其中 已经引入或破坏了2871,14926,44576,23992,1983,52881,2398或52872基因。 本发明还进一步提供了分离的2871,14926,4457,239992,1983,52881,2398或52872蛋白质，融合蛋白，抗原肽和抗-2871,14926,4457,23992,1983,52881,29898或52872抗体。 还提供了利用本发明组合物的诊断方法。

    3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor
    9.
    发明申请
    3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor 审中-公开
    3714,16742,23546和13887新型蛋白激酶分子及其用途

    公开(公告)号：US20070178515A1

    公开(公告)日：2007-08-02

    申请号：US11726163

    申请日：2007-03-21

    申请人： Rachel Meyers ,  John Hunter

    发明人： Rachel Meyers ,  John Hunter

    IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C12N9/12

    CPC分类号： C12N9/1205 ,  C12Q1/48 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156

    摘要： The invention provides isolated nucleic acids molecules, designated 3714, 16742, 23546, or 13887 nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 3714, 16742, 23546, or 13887 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 3714, 16742, 23546, or 13887 gene has been introduced or disrupted. The invention still further provides isolated 3714, 16742, 23546, or 13887 proteins, fusion proteins, antigenic peptides and anti-3714, -16742, -23546, or -13887 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供编码新的蛋白激酶的分离的核酸分子，命名为3714,16742,23546或13887核酸分子。 本发明还提供反义核酸分子，含有3714,16742,23546或13887核酸分子的重组表达载体，已经引入表达载体的宿主细胞，以及非人类转基因动物，其中3714,16742,23546或 13887基因已被引入或破坏。 本发明还进一步提供分离的3714,16742,23546或13887蛋白，融合蛋白，抗原肽和抗-3714，-16742，-23546或-13887抗体。 还提供了利用本发明组合物的诊断，筛选和治疗方法。

    Fluid control
    10.
    发明授权
    Fluid control 有权
    流体控制

    公开(公告)号：US08474484B2

    公开(公告)日：2013-07-02

    申请号：US12087255

    申请日：2006-12-29

    申请人： Eugene Vladimirovich Stepanov ,  Douglas P. Goulet ,  John Hunter

    发明人： Eugene Vladimirovich Stepanov ,  Douglas P. Goulet ,  John Hunter

    IPC分类号： F15D1/02

    CPC分类号： F16L55/02781 ,  F16K47/08 ,  F16K47/10 ,  Y10T137/86718 ,  Y10T137/86759

    摘要： A valve trim for a pressure reduction valve containing a plurality of high hydraulic flow resistance flowpaths therethrough. Each flowpath comprises at least two inlets (208, 209) and at least one impingement zone (210) having two zone inlets (211, 212) and two zone outlets (213, 214). The zone inlets (211, 212) communicate with the inlets (208, 209) and are arranged substantially 180 degrees to one another. The two zone outlets (213, 214) are arranged substantially perpendicular to the zone inlets (211, 212) such that flow entering the two zone inlets (211, 212) mutually impinges on itself creating an area of high energy loss, and thereafter separates and exits through the zone outlets (213, 214).

    摘要翻译： 一种用于减压阀的阀门装置，其包含通过其中的多个高液压阻力流路。 每个流路包括至少两个入口（208,209）和至少一个具有两个区域入口（211,212）和两个区域出口（213,214）的冲击区域（210）。 区域入口（211,212）与入口（208,209）连通并且彼此大致180度地布置。 两个区域出口（213,214）被布置成基本上垂直于区域入口（211,212），使得进入两个区域入口（211,212）的流相互撞击在自身上，形成高能量损失的区域，然后分离 并通过区域出口（213,214）离开。